Ultragenyx Pharmaceutical RARE reported second-quarter 2025 loss of $1.17 per share, narrower than the Zacks Consensus ...

The demand for renal transplant therapeutics is increasing due to several important factors. Chief among these is the global rise in kidney transplan ...

Bayer AG (BAYRY) reported second-quarter 2025 core earnings of 35 cents per American Depositary Receipt (ADR), which ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

The FDA reviews odronextamab's application for relapsed lymphoma, highlighting trial enrollment issues but confirming safety and efficacy.

AstraZeneca, which last week announced a $50bn plan for US development, declined to comment. Pfizer, Abbvie, and Germany’s ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

In patients with diabetic macular edema in both eyes, the port delivery system in one eye achieves a superior anatomical ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

The FDA issued another complete response letter for odronextamab for the treatment of relapsed/refractory follicular lymphoma.

Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.

LONG BEACH, Calif. -- Depletion of a payment assistance program has translated into worse vision outcomes for older patients ...